Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2023/06/054158
CTRI/2023/06/054158Not yet recruitingPhase 3

A Comparative clinical study to evaluate the efficacy of Paarthadi Kwath along with Hridbasti and calcium channel blocker on Essential Hypertension

DPU Seed Money with letter no DPU1 site in 1 country40 target enrollmentStarted: January 7, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 3
Status
Not yet recruiting
Sponsor
Enrollment
40
Locations
1
Primary Endpoint
Patient showing relief from clinical sign and symptoms of essential hypertension.
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

A group of 20 patients will get Paarthadi Kwath along with Hridbasti for a period of 7 days. Another group of 20 patients will get Tab. Stamlo 2.5mg for 7 days. Data will be collected and compared.

Study Design

Study Type
Interventional
Allocation
Computer generated randomization
Masking
Open Label

Eligibility Criteria

Ages
0.00 Day(s) to 7.00 Day(s) (—)
Sex
All

Inclusion Criteria

  • •18-70 years of either gender.
  • •Systolic Blood pressure less than 170mmHg more than or equal to 140mmHg.
  • •Distolic Blood Pressure less thann or equal to 110mmHg and more than 90mmHg.
  • •Hypertension Stage II according to JNC seventh report 2004.

Exclusion Criteria

  • •Patient that past history of atrial fibrillation, acute coronary syndrome ,myocardial infarction, stroke, right ventricular hypertrophy, left ventricular hypertrophy, severe arrhythmia in last 6 months.
  • •Symptomatic patient with clinical feature of early heart failure.
  • •Secondary hypertension.
  • •Patient with concurrent serious hepatic dysfunction, renal dysfunction, uncontrolled pulmonary dysfunction.
  • •Patient suffering with diabetes nephropathy.
  • •Women who are pregnant, lactating or on estrogen replacement therapy.
  • •Alcohol and Drug abusers.
  • •Accelerated and maligant hypertension.

Outcomes

Primary Outcomes

Patient showing relief from clinical sign and symptoms of essential hypertension.

Time Frame: 0, 4 and 7 day

Secondary Outcomes

  • To complete seven days treatment(0, 4 and 7 day)

Investigators

Sponsor
DPU Seed Money with letter no DPU
Sponsor Class
Research institution and hospital

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Phase 2/3
Evaluate the effect of Madhukadi Lauha in Timir w.s.r. to Myopia
CTRI/2023/04/051838Principal, RGGPG Ayurvedic College& Hospiyal Paprola, Kangra20
Not yet recruiting
Phase 2/3
A study to compare the efficacy of Pathyadi Kwath and Rasnadi Kwath in the management of Ardhavbhedak (Migraine)
CTRI/2025/03/083352Madan Mohan Malviya Government Ayurveda College Udaipur60
Recruiting
Not Applicable
Role of khadirastak kwatha and somraji taila (external application) in the treatment of vicharchika (dry eczema)
CTRI/2017/02/007771Government Akhandanand Ayurved college and Hospital30
Recruiting
Not Applicable
management of rheumatoid arthritis with Ayurvedic drugs.
CTRI/2017/02/007869Govt Akhandanand Ayurved college and hospital and Maniben Ayurved Hospital30
Not yet recruiting
Phase 3
A clinical trial to study effect of Katphal deccoction gargles and Triphaladi deccoction gargles in management of dental caries
CTRI/2022/12/047942Tilak Ayurved Mahavidyalay Pune70